Interventions of Interest:
- Tezepelumab (Tezpire, Amgen/AstraZeneca)
ICER’s Evidence Report Findings:
Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic therapies; tezepelumab would achieve common thresholds for cost-effectiveness if priced between $9,000 – $12,100 per year.
Recommendations for fair access include ensuring that all biologic options be available for patients with severe asthma due to variation in treatment response and common failure of first biologic therapy to achieve clinical goals.
Final Documents
For more information, please contact info@icer.org.
View the Key Stakeholder List
David Rind, MD, ICER’s Chief Medical Officer stated:
“ICER previously reviewed biologic therapies for moderate-to-severe asthma, and none of those available at that time were effective in patients without allergic or eosinophilic asthma.Tezepelumab has a new mechanism of action and does reduce exacerbations even for patients without eosinophilia who really have not had good options for treatment until now. For other asthma patients for whom biologics are available, tezepelumab is not clearly superior to those options, and it may be less effective at getting patients off oral steroids than dupilumab.”
Public Comments
Closed